Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sanjay Ramakumar

Urology Phoenix, AZ Medical Doctor

NPI 1437255742 CMS profile 292518

2122 E Highland Ave Ste 100, Phoenix, AZ 85016

Open in the dashboard

General payments

$7,198

115 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$11,982 paid to institutions, not to them · program year 2019

Through program year 2025, Sanjay Ramakumar of Phoenix, AZ is reported in the CMS Open Payments database as having received $7,198 across 115 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $11,982 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 74th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,122 6
2024 General $1,857 12
2023 General $2,796 52
2022 General $558 6
2021 General $24 1
2020 General $207 3
2019 General $635 35

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sanjay Ramakumar
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Sanjay Ramakumar were reported at $1,122. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Sanjay Ramakumar Urology median Middle half National median
2019 $635 $480 $147–$1,201 $163
2020 $207 $246 $87–$645 $114
2021 $24 $358 $111–$1,000 $132
2022 $558 $476 $143–$1,263 $149
2023 $2,796 $560 $168–$1,461 $160
2024 $1,857 $563 $170–$1,464 $164
2025 $1,122 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $3,971 25 payments
  2. PROCEPT BioRobotics Corporation $569 11 payments
  3. Teleflex LLC $560 9 payments
  4. Boston Scientific Corporation $411 6 payments
  5. Sumitomo Pharma America, Inc. $248 3 payments
  6. Dendreon Pharmaceuticals LLC $213 9 payments
  7. CONMED Corporation $198 2 payments
  8. Coloplast Corp $191 10 payments
  9. Innovation Technologies Inc $116 1 payment
  10. Ambu Inc. $103 4 payments
  11. Other $618 35 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,919 100 payments
  2. Travel and Lodging $2,061 13 payments
  3. Gift $218 2 payments
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $3,630 22 payments
  2. AQUABEAM ROBOTIC SYSTEM $569 11 payments
  3. UROLIFT $346 9 payments
  4. DA VINCI SP $341 3 payments
  5. ORGOVYX $248 3 payments
  6. BARRIGEL $223 2 payments
  7. PROVENGE $213 9 payments
  8. AIRSEAL $198 2 payments
  9. LithoVue $121 1 payment
  10. Irrisept $116 1 payment
  11. Other $984 57 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

327

Median for Urology: 1,053

Drug cost

$411,623

Median for Urology: $101,464

Branded share of claims

26.3%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtandi Enzalutamide Brand 20 $277,061
Orgovyx Relugolix Brand 47 $133,471
Tamsulosin Hcl Generic 56 $469
Finasteride Generic 30 $245
Trospium Chloride Generic 12 $114
Ciprofloxacin Hcl Generic 100 $88
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 19 $78
Gabapentin Generic 16 $57
Tramadol Hcl Generic 27 $41

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 68 billing codes

Paid by Medicare

$109,550

Medicare's payments for the services billed

Medicare patients

475

Average age 75

Services billed

1,428

91 women, 384 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 45%
Cancer 39%
Ischemic heart disease 37%
Chronic kidney disease 36%
Diabetes 27%
Atrial fibrillation 23%
Heart failure 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

115 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record